Grifols, S.A. (NASDAQ:GRFS - Get Free Report) was down 2.7% during trading on Friday . The company traded as low as $7.48 and last traded at $7.51. Approximately 203,161 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 1,823,070 shares. The stock had previously closed at $7.72.
Wall Street Analysts Forecast Growth
Separately, Berenberg Bank upgraded Grifols to a "strong-buy" rating in a report on Tuesday, October 29th.
Get Our Latest Analysis on Grifols
Grifols Price Performance
The firm's fifty day simple moving average is $8.37 and its 200-day simple moving average is $8.10. The firm has a market capitalization of $5.16 billion, a PE ratio of 7.74 and a beta of 0.43. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11.
Institutional Trading of Grifols
Several institutional investors have recently added to or reduced their stakes in GRFS. GAMMA Investing LLC lifted its holdings in shares of Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 1,135 shares in the last quarter. Signaturefd LLC raised its position in Grifols by 66.2% in the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company's stock worth $48,000 after buying an additional 2,153 shares during the last quarter. HighTower Advisors LLC lifted its stake in Grifols by 12.5% during the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company's stock valued at $123,000 after acquiring an additional 1,546 shares during the period. AQR Capital Management LLC purchased a new stake in shares of Grifols during the 2nd quarter valued at about $89,000. Finally, Chesapeake Capital Corp IL bought a new stake in shares of Grifols in the third quarter worth approximately $148,000.
Grifols Company Profile
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
See Also
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
